Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Mar 21, 2025; 31(11): 100911
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.100911
Table 2 Baseline characteristics of patients in validation group, n (%)
Variables
Total (n = 89)
Textbook outcome (n = 49)
None-textbook outcome (n = 40)
P value
Age, M (Q1, Q3)58.00 (48.00, 65.00)59.00 (53.00, 64.00)56.50 (46.75, 65.00)0.501
Sex0.167
    Male53 (59.55)26 (53.06)27 (67.50)
    Female36 (40.45)23 (46.94)13 (32.50)
Hepatitis B0.190
    Negative64 (71.91)38 (77.55)26 (65.00)
    Positive25 (28.09)11 (22.45)14 (35.00)
ECOG score0.001
    032 (35.96)25 (51.02)7 (17.50)
    157 (64.04)24 (48.98)33 (82.50)
Child-Pugh0.017
    A57 (64.04)26 (53.06)31 (77.50)
    B32 (35.96)23 (46.94)9 (22.50)
Tumor size, M (Q1, Q3)6.50 (5.00, 8.40)6.70 (4.70, 8.40)6.50 (5.00, 8.27)0.853
Tumor number0.104
    Solitary66 (74.16)33 (67.35)33 (82.50)
    Multiple23 (25.84)16 (32.65)7 (17.50)
TBIL, M (Q1, Q3)17.20 (10.70, 33.10)19.00 (10.60, 41.50)16.00 (11.18, 28.75)0.668
DBIL, M (Q1, Q3)7.90 (4.60, 12.70)8.90 (5.10, 12.70)6.45 (4.33, 12.25)0.203
CA19-9, M (Q1, Q3)109.10 (13.90, 778.00)192.70 (17.60, 1000.00)83.95 (8.10, 485.52)0.073
AFP, M (Q1, Q3)6.20 (2.70, 97.60)5.10 (2.40, 97.60)6.95 (2.70, 74.53)0.738
CEA, M (Q1, Q3)2.70 (1.80, 4.79)2.50 (1.70, 3.70)3.10 (2.00, 10.67)0.030
Blood transfusion0.008
    No82 (92.13)49 (100.00)33 (82.50)
    Yes7 (7.87)0 (0.00)7 (17.50)
Surgical margins0.008
    Negative82 (92.13)49 (100.00)33 (82.50)
    Positive7 (7.87)0 (0.00)7 (17.50)
Complications< 0.001
    No70 (78.65)49 (100.00)21 (52.50)
    Yes19 (21.35)0 (0.00)19 (47.50)
Perioperative death or readmission within 30 days after discharge0.08
    No85 (95.51)48 (100.00)37 (90.00)
    Yes4 (4.49)0 (0.00)4 (10.00)
Prolonged hospitalization< 0.001
    No57 (64.04)49 (100.00)8 (20.00)
    Yes32 (35.96)0 (0.00)32 (80.00)